Charlie Munger: End-of-Life Chemotherapy Shouldn’t Be About Profit
Berkshire Hathaway vice chair Charlie Munger criticized end-of-life cancer treatment as often pointless, costly, and driven by financial incentives, calling it ‘evil’ and ‘asinine’ to pour chemotherapy into patients who are essentially dead; he argued there’s a point when medicine should stop and contemplated broader U.S. healthcare reform ideas, including single-payer-style approaches, noting the large role of costs in the economy.
